#NewMemberAseBio | 'AseBio is an excellent association that brings together the most important pharmaceutical and biotech companies in the Spanish market under one roof'
Meet Zeta GmbH, our new member. We talked to Andreas Marchler, CEO of the company and with Christine Kolland, Business Development in Spain.
AseBio. What does your company's work bring to the table and what is its strength?
Andreas Marchler. With more than 1,300 highly qualified employees and 27 locations worldwide, ZETA specializes in the design, construction, automation, digitalization and qualification of customized biopharmaceutical plants for aseptic process solutions. We are a true end-to-end solution provider, combining plant engineering with HVAC and cleanroom design.
One of the great advantages that we offer our customers is that we support from phase I to IV along the manufacturing process of active substances with sophisticated solutions from the laboratory to industrial production.
ZETA is also taking steps towards a more sustainable future for the industry as a whole. Thanks to our holistic decarbonization strategies, emissions are reduced during the biopharmaceutical manufacturing process, well-coordinated for both production facilities and the infrastructure. We get our customers ready for reaching the climate goals by accompanying them on their way to net zero.
On the Spanish market, we are looking for new cooperations in the biotech and biopharma industry. We will support Spanish companies in scaling up their processes from laboratory to production and in optimizing their processes or revamping their existing facilities.
Our expertise and solutions are aimed at startups, looking for an experienced partner in order to find the right solution for the production of new drugs, all the way to biotech companies who need an experienced process partner for establishing a complete biotech facility.
AseBio. What is AseBio for you?
Christine Kolland. For us, AseBio is an excellent association that brings together the most important pharmaceutical and biotech companies in the Spanish market under one roof. It is the place to be for creating new partnerships, learn from each other and tackle the most pressing challenges of the industry.
AseBio. When did you first hear about AseBio?
Christine Kolland. When we decided to strengthen our presence on the Spanish market, we were looking for a first-class platform for networking. In our research on events, promotion platforms and networks for the Spanish biotech sector, we kept coming across AseBio. In addition, our Spanish business partner, who is well established in the market, has strongly encouraged us to become a member of AseBio.
AseBio. What do you expect from being part of an association like AseBio?
Christine Kolland. We want to drive the pharmaceutical and biotech industry in Spain with our sophisticated solutions and innovative products. This can only be achieved with like-minded partners, which is where AseBio comes into play: The advantage of an association like AseBio is that we as a company can access a large and strong network of such kind of partners and innovative companies.
Another important service is the organization of events and conferences. A special highlight, which I am personally looking forward to, is BIOSPAIN in Barcelona, where we hope to meet and exchange ideas with innovative minds of the biotech industry.
AseBio. What is the biggest challenge facing the biotech sector (or your company)?
Andreas Marchler. The two biggest challenges for us at the moment are the availability of qualified personnel and the availability of various materials. Delivery times for raw materials, semi-finished products, electronic components and transportation services are expected to ease, but prices for these services and products will continue to rise. ZETA has established an active supplier management system to counter supply chain problems as early as possible. This will allow future risks in procurement to be kept under control.
Recruiting well-trained personnel is a major challenge for the entire industry. Training in the specifics of the pharmaceutical industry is done in-house at ZETA. Continuing education is considered a basic prerequisite for survival. The industry-specific detailed knowledge can only be learned within the company. We have therefore decided to try out new approaches as well.
By expanding our completely digital engineering platform, internal processes and interfaces can be handled in a time- and cost-saving manner. Our platform also allows us to provide the data of a project to the customer to be used for efficient operation, training and maintenance.
This also enables new colleagues to familiarize themselves more quickly with complex topics - no matter where they are in the world.
We are looking forward to working on all these challenges with our Spanish partners and successfully realizing new projects together.